SAEs the only similarity between the BIA 10-2474 trial and 'elephant man' study, says MHRA

By Gareth Macdonald contact

- Last updated on GMT

ANSM investigating BIA 10-2474 trial in which one volunteer died
ANSM investigating BIA 10-2474 trial in which one volunteer died

Related tags: Clinical trial, United kingdom

A study halted in France after one volunteer died and others were injured differs markedly from the disastrous “elephant man” trial that hospitalized six in the UK in 2006 according to the MHRA.

Biotrial stopped the Phase I trial of BIA 10-2474 last week, prompting observers such as Sky News​ and the Telegraph​ to liken the incident to a UK trial that was suspended in 2006​.

But any similarities to the earlier TGN1412 trial - later dubbed the "elephant man"​ study - are circumstantial says the MHRA, which told us the programmes had nothing in common in terms of protocols or in how they were conducted.

This is in keeping with information provided by French authorities so far.

According to Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) the “trial was approved last June 26…and received a favorable opinion from the Comité de Protection des Personnes Ouest VI​ [an independent review panel] on July 3, 2015​.”

The Agency said the six injured volunteers had received “multiple” high doses of BIA 10-2474, which is a painkiller being developed by Portugal-based drugmaker Bial-Portela & Ca.

It also said no serious adverse events (SAEs) occurred during single-dose phases of the study.

This is in marked contrast with the TGN1412 trial in which the administration of a single dose of the drug – an antibody being trialled for autoimmune disorders by TeGenero Immuno Therapeutics – caused multiple organ failure in six volunteers​.

Regulations

The other key difference between the BIA 10-2474 and TGN1412 studies is that all the volunteers in the latter programme eventually recovered​.

Earlier today ANSM confirmed that one of the men hospitalised in the BIA 10-2474 trial had died. The other five men are being treated at University hospital in Rennes.

A report on the TGN1412 study prompted the UK to introduce a voluntary accreditation scheme​ for early phase research. It also moved the EMA to adopt new guidelines on the preclinical testing​ and rejig the rules on first-in-man studies​.

Whether the BIA 10-2474 tragedy is followed by a similar reassessment remains to be seen. 

TGN1412 reborn

The “elephant man” study was not the end of the road for TGN 1412​. The drug was bought by Russia’s TheraMab and renamed TAB08.

TAB08 is being tested as a treatment for autoimmune disorders and – according to an article in the British Medical Journal (BMJ) – is due to enter Phase II trials having shown promise in a Phase I study​ carried out in London last year. 

Related topics: Clinical Development, Phase I-II

Related news

Show more

Related products

show more

Next generation ePRO from SQN Health

Next generation ePRO from SQN Health

Syne Qua Non Clinical | 16-May-2018 | Business Advice

In an era of rapid technology growth, healthcare requires low cost solutions for real-time data collection. We have come a long way from paper to EDC and...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars